AI assistant
PIRAMAL PHARMA LIMITED — Call Transcript 2023
Feb 1, 2023
59525_rns_2023-02-01_81bc3128-2308-45bd-b52e-26112ef4520d.pdf
Call Transcript
Open in viewerOpens in your device viewer
==> picture [145 x 60] intentionally omitted <==
01[st ] February, 2023
BSE Limited P.J. Towers, Dalal Street, Fort, Mumbai- 400 001 BSE scrip code: 543635
National Stock Exchange of India Limited Exchange Plaza, Bandra-Kurla Complex, Bandra (East), Mumbai – 400 051 NSE symbol: PPLPHARMA
Sub: Intimation of Conference Call with Investors/Analysts under the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 (‘Listing Regulations’)
Dear Sir / Madam,
Pursuant to Regulation 30(6) of the Listing Regulations, please find enclosed herewith the details of the Conference Call with investors/ analysts.
Kind take this on record.
Thanking you,
Yours truly,
For Piramal Pharma Limited
Digitally signed TANYA by TANYA SANISH SANISH Date: 2023.02.01 15:51:15 +05'30'
Tanya Sanish Company Secretary
Piramal Pharma Limited CIN: U24297MH2020PLC338592 Registered Office: Gr. Flr. Piramal Ananta, Agastya Corporate Park, Opp Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai – 400070 India T +91 22 3802 3000 / 4000
piramal.com
==> picture [145 x 60] intentionally omitted <==
Q3 and 9M FY2023 Earnings Conference Call
Piramal Pharma Limited will be hosting a conference call for investors / analysts on 9[th] February 2023 at 5:00 PM (IST) to discuss its Q3 and 9M FY2023 Results.
The dial-in details for the call are as under:
| Event | Location & Time | Telephone Number |
|---|---|---|
| Conference call on 9thFebruary, 2023 |
India – 5:00 PM IST | +91 22 6280 1461 / +91 22 7115 8320 (Primary Number) |
| 1 800 120 1221(Toll free number) | ||
| USA – 6:30 AM (Eastern Time – New York) |
Toll free number 18667462133 |
|
| UK – 11:30 AM (London Time) |
Toll free number 08081011573 |
|
| Singapore – 7:30 PM (Singapore Time) |
Toll free number 8001012045 |
|
| Hong Kong – 7:30 PM (HongKongTime) |
Toll free number 800964448 |
|
| Express Join with Diamond Pass™ |
Please use this link for prior registration to reduce wait time at the time of joining the call – https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber =3875819&linkSecurityString=132719d2f8 |
About Piramal Pharma Ltd:
Piramal Pharma Limited (PPL, NSE: PPLPHARMA | BSE: 543635), a leading global pharmaceuticals company, offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 15 global facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated Contract Development and Manufacturing Organization; Piramal Critical Care (PCC), a Complex Hospital Generics business; and the India Consumer Healthcare business, selling over-the-counter products. In addition, PPL has a joint venture with Allergan, a leader in ophthalmology in the Indian formulations market. In October 2020, PPL received 20% strategic growth investment from the Carlyle Group.
For more information visit: https://www.piramal.com/pharma/, Facebook, Twitter, LinkedIn
For Media Queries: Rajiv Banerjee Group Head - Corporate Communications [email protected]
For Investors: Gagan Borana General Manager - Investor Relations & Sustainability [email protected]
Piramal Pharma Limited
CIN: U24297MH2020PLC338592 Registered Office: Gr. Flr. Piramal Ananta, Agastya Corporate Park, Opp Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai – 400070 India T +91 22 3802 3000 / 4000
piramal.com